Business Description
Santarus, Inc.
ISIN : US8028173040
Compare
Compare
Traded in other countries / regions
TW4A.Germany Description
Santarus, Inc. was incorporated on December 6, 1996 as a California corporation and did not commence significant business activities until late 1998. On July 9, 2002, the Company reincorporated in the State of Delaware. The Company is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. It sells brand prescription products primarily to pharmaceutical wholesalers, who in turn seek to distribute the products to retail pharmacies, mail order pharmacies, hospitals and other institutional customers. The Company's current commercial efforts are focused on five products: UCERIS, extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists; GLUMETZA and CYCLOSET tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; and FENOGLIDE tablets, which is indicated as an adjunct to diet to reduce high cholesterol. The pipeline products include the investigational drug RUCONEST for treatment of acute attacks of hereditary angioedema.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Debt-to-EBITDA | 0.12 | |||||
| Interest Coverage | 253.29 |
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | 24.05 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 18.4 | |||||
| PE Ratio without NRI | 18.4 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Santarus, Inc. Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 256.464 | ||
| EPS (TTM) (€) | 1.247 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 0 - 23 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Santarus, Inc. Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Santarus, Inc. Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Santarus, Inc. Frequently Asked Questions
What is Santarus, Inc.(FRA:TW4A)'s stock price today?
The current price of FRA:TW4A is €23.00. The 52 week high of FRA:TW4A is €23.00 and 52 week low is €0.00.
When is next earnings date of Santarus, Inc.(FRA:TW4A)?
The next earnings date of Santarus, Inc.(FRA:TW4A) is .
Does Santarus, Inc.(FRA:TW4A) pay dividends? If so, how much?
Santarus, Inc.(FRA:TW4A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers